Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2006-05-23
2006-05-23
Nazario-Gonzalez, Porfirio (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S086000, C564S087000, C564S089000, C564S092000, C514S602000
Reexamination Certificate
active
07049468
ABSTRACT:
Compounds of formula 1 modulate the activity of Rho C:whereinR is a direct bond, lower alkylene, —C(O)NH—, or —NHC(O)—;Ar is aryl or heteroaryl, substituted with R7, R8, R9, and R10, wherein R7, R8, and R9are each independently H, halo, lower alkyl, OH, lower alkoxy, and R10is H, halo, lower alkyl, OH, lower alkoxy, or forms a ring with R1;R1is H, lower alkyl, or forms a ring with R10;R2, R3, R4, R5, and R6are each independently H, lower alkyl, halo, nitro, OH, lower alkoxy, NH2, lower alkylamino, di(lower alkyl)amino, or two adjacent groups together form a saturated or unsaturated ring;or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 6121488 (2000-09-01), Nikam
patent: 08208613 (1986-08-01), None
patent: 2000089428 (2000-03-01), None
patent: 2001-293964 (2001-10-01), None
patent: WO 99/24563 (1999-05-01), None
patent: WO 995566 (1999-11-01), None
Katsumi et al, Journal of Medicinal Chemistry, (1989), vol. 32 (3), pp. 583-593, CA 1988:114792.
Lukanov et al, Synthesis, (1987) vol. 2, pp. 204-206., CA 1987:496573.
White et al, JACS, 1994) vol. 116 (5), pp. 1831-1838, CA 1994:218259.
Aktories, “Rho proteins: targets for bacterial toxins,”Trends Microbiol. 5(7):282-288, 1997.
Boman et al., “Arf proteins: the membrane traffic police?”Trends Biochem. Sci. 20(4):147-150, 1995.
BOS, “ras Oncogenes in human cancer: a review,”Cancer Res. 49(17):4682-4689, 1989.
Cerione et al., “The Dbl family of oncogenes,”Curr. Ipin. Cell Biol. 8(2):216-222, 1996.
Chavrier et al., “The role of ARF and Rab GTPases in membrane transport,”Curr. Opin. Cell Biol. 11(4):466-475, 1999.
Clark et al., “Genomic analysis of metastasis reveals an essential role for RhoC,”Nature406:532-535, 2000.
END, “Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway,”Invest New Drugs17(3):241-258, 1999.
Fritz et al., “Rho GTPase are over-expressed in human tumors,”Int. J. Cancer81(5):682-687, 1999.
Ganguly et al., “Detection and structural characterization of Ras oncoprotein-inhibitors complexes by electrospray mass spectrometry,”Bioorg. Med. Chem. 5(5):817-820, 1997.
Ganguly et al., “Interaction of a novel GDP exchange inhibitor with the Ras protein,”Biochemistry37(45):15631-15637, 1998.
Hall, “Ras-related proteins,”Curr.Opin. Cell Biol. 5(2):265-268, 1993.
Hall, “Rho GTPases and the actin cytoskeleton,”Science279:509-514, 1998.
Helliwell et al., “The Rhol effector Pkel, but not Bnil, mediates signalling from Tor2 to the actin cytoskeleton,”Curr. Biol. 8(22):1211-1214, 1998.
Ihara et al., “Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue,”J. Biol. Chem. 273(16):9656-9666, 1998.
Kaibuchi et al., “Regulation of the cytoskeleton and cell adhesion by the Rho family CTPases in mammalian cells,”Ann. Rev. Biochem. 68:459-486, 1999.
Kohl. “Farnesyltransferase inhibitors preclinical development,”Ann. NY Acad. Sci. 886:91-102, 1999.
Kumar et al., “SCH 51344, an inhibitor of Ras/Rac-mediated cell morphology pathway,”Ann. NY Acad. Sci. 886:122-131, 1999.
Longenecker et al., “How RhoGDI binds Rho,”Acta Crystallogr. D. Biol. Crystallogr55(Pt 9):1503-1515, 1999.
Mackay et al., “Rho GTPases,”J. Biol. Chem. 273:20685-20688, 1998.
Maesaki et al., “The structural basis of Rho effector recognition revealed by the crystal structure of human RhoA complexed with effector domain of PKN/PRK1,”Mol. Cell4(5):793-803, 1999.
Maesaki et al., “Biochemical and crystallographic characterization of a Rho effector domain of the protein serine/threonine kinase N in a complex with RhoA,”J. Struct. Biol. 126:166-170, 1999.
Martinez et al., “Rab proteins,”Biochem Biophys Acta1404(1-2):101-112, 1998.
Moore, “Ran and nuclear transport,”J. Biol. Chem. 273(36):22857-22860, 1998.
Nomanbhoy et al., “Kinetics of cdc42 membrane extraction by Rho-GDI monitored by real-time fluorescence resonance energy transfer,”Biochemistry38(6):1744-1750, 1999.
Read et al., “Human RhoA/RhoGDI complex expressed in yeast: GTP exchange is sufficient for translocation of RhoA to liposomes,”Protein Sci. 9(2):376-386, 2000.
Rittinger et al., “Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP,”Nature388:693-697, 1997.
Rush et al., “The small nuclear GTPase ran: how much does it run?”Bioessays18(2):103-112, 1996.
Schmidt et al., “Bacterial cytotoxins target Rho GTPases,”Naturwissenschaften85(6):253-261, 1998.
Schimmöller et al., “Rab GTPases, directors of vesicle docking,”J. Biol. Chem. 273(35):22161-22214, 1998.
Shimizu et al., “An open conformation of switch I revealed by the crystal structure of a Mg2+ free form of RHOA complexed with GDP,”J. Biol. Chem. 275(24):18311-18317, 2000.
Suwa et al.,“Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas,”Br. J. Cancer77(1): 147-152, 1998.
Tanaka et al., “Control of reorganization of the actin cytoskeleton by Rho family small GTP-binding proteins in yeast,”Curr. Opin. Cell Biol. 10(1):112-116, 1998.
Taveras et al., “Ras oncoprotein inhibitors: the discovery of potent, Ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex,”Bioorg. Med. Chem. 5(1):125-133, 1997.
Vojtek et al., “Increasing complexity of the Ras signaling pathway,”J. Biol. Chem. 273(32):19925-19928, 1998.
Watanabe et al.,“Cooperation between mDial and ROCK in Rho-induced actin reorganization,”Nat. Cell Biol. 1(3):136-143, 1999.
Whitehead et al., “Dbl family proteins,”Biochem. Biophys. Acta1332(1):F1-23, 1997.
Yoshioka et al., “Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells,”Cancer Res. 59(8):2004-2010, 1999.
Perkins Edward L.
Sun Dongxu
Tugendreich Stuart
Howrey LLP
Iconix Pharmaceuticals Inc.
Nazario-Gonzalez Porfirio
Whiting Adam K.
LandOfFree
Modulators of Rho C activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of Rho C activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of Rho C activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594845